BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
UK can legally stop shadow fleet tankers, ministers believe - 2Israel scales back use of top missile interceptors as Iran barrages persist
- 3Here's what the Artemis 2 astronauts will be doing on each day of NASA's historic moon mission
- 4My Excursion to Monetary Autonomy: Awesome ways to save cash
- 5IDF Givati Brigade soldier arrested, charged in suspected Iran espionage
- Getting ready for a Mechanized World: 10 Positions That computer based intelligence Could Dominate
- Famous Network programs in Europe and America
- What is the 'Survivor 50' Challenge? Hidden immunity idols will be up for grabs in every U.S. state.
- Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
- Vote In favor of Your Number one Sort Of Blossoms
- Child influencers helped power a booming industry. It's time for a reckoning.
- Brexit's Effect on New York's Ascent as a Main Monetary Center
- What to know about the hepatitis B shot — and why Trump officials are targeting it
- Vote In favor of Your Favored Menial helper Administration
